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SHORT COMMUNICATION
CA125 in ovarian tumour tissue at second laparotomy
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South Wales Radiotherapy and Oncology Service, Velindre Hospital, Whitchurch, Cardiff CF4 7XL and 'Pathology
Department, University of Wales College of Medicine, Cardiff CF4 4XW, UK.
The difficulty in clinical assessment of patients with ovarian
cancer has led to a search-for a sensitive tumour marker.
The tumour associated antigen CA125 is thought to be the
most useful currently available (Bast et al., 1983; Milford
Ward, 1987). It is present in the tumour tissue of over 80%
of ovarian carcinomas at first laparotomy (Kabawat et al.,
1983; Koelma et al., 1987; Maughan et al., 1988). Serum
antigen levels are elevated in over 60% of patients and
appear to correlate with the clinical course of the disease
(Bast et al., 1983; Canney et al., 1984; Fish et al., 1987).
Elevated serum levels after chemotherapy have been found
to predict for the presence of residual disease at second
laparotomy (Niloff et al., 1985; Alvarez et al., 1987; Fish et
al., 1987). However, one limitation of serum CA125 moni-
toring is that the majority of patients with serum levels
falling into the normal range after chemotherapy still have
residual disease at second laparotomy (Niloff et al., 1985;
Fish et al., 1987). The reason for this phenomenon is unclear
but one possibility is that chemotherapy selectively kills
tumour cells that produce CA125. In order to investigate
this, the present study examines tumour material from
patients with residual disease at second laparotomy and
compares antigenic staining before and after chemotherapy.
Thirteen patients (mean age 52.7 years), who had residual
tumour after first laparotomy (lap 1), received 5-monthly
courses of platinum therapy (cisplatin 100mgm-2 in 11,
carboplatin 400mgm-2 in two). Thereafter they had no
detectable disease on clinical and ultrasound examination
and were assessed at a second laparotomy (lap 2). The
patients were reclassified according to the findings at lap 2
as having residual disease of 2-10cm (n=4), <2cm (n=7)
or as CR+ (disease present on peritoneal washing only,
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n =2). The clinical and pathological data are shown in
Table I.
The presence of CA125 was assessed on formalin-fixed,
paraffin-embedded tumour tissue from first and second
laparotomies using an avidin-biotin-peroxidase technique
(Koelma et al., 1987). Distribution of the antigen was
estimated on histology sections and classified as negative (-);
scanty, <5% tumour cells stained (+); moderate, 5-33%
(+ +); orwidespread, >33% (+ + +). Control slides omitting
the primary antibody (OC-125, available from CIS (UK)
Ltd, High Wycombe, UK) were used for all cases. When
cytology specimens only were available, CA125 was assessed
as present (+(c))'or absent (O(c)) on positive cytology slides
which had been decolorised in 1% acid alcohol and restained
with the same immunoperoxidase method. In three cases
(patients 2, 10, 13) 15 tumour blocks were examined per
patient to assess antigen heterogeneity.
Serum CA125 concentrations were estimated 3 weeks after
lap 1 and at the end of chemotherapy using an immuno-
radiometric assay (Shelley & Fish, 1986) which used the
same monoclonal antibody (OC 125) as in the immuno-
peroxidase methodology. The upper limit of the normal
serum concentration was taken as 35 units ml- 1 (Bast et al.,
1983).
CA125 was detected in tumour tissue or peritoneal wash-
ings in all 13 patients from lap 1 and in 12 from lap 2 with
widespread staining (+ + +) in the majority ofcases. Analysis
of multiple sections from three patients showed widespread
antigen staining in all sections from two cases, with no
discernible alteration in pattern or intensity of staining from
first to second laparotomies (patients 2, 10). Patient 13
showed a heterogeneous pattern, with areas of positive
staining on five of 15 sections, but focal areas of positivity
could be detected in tissue both before and after chemo-
therapy.
Serum antigen levels were elevated after lap I in 10
patients and, during chemotherapy, remained elevated in six
Table I Clinical data and CA125 results in ovarian carcinoma
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but fell into the normal range in four cases. The remaining
three patients, each of whom had less than 2cm residuum
after lap 1, had normal serum CA125 levels initially.
All six patients in whom serum CA125 concentrations
were in the normal range before their second laparotomy
had CA125 detected in tumour tissue removed at lap 2. The
false-negative serum CA125 results are therefore not due to
the irradication of antigen-producing cells by chemotherapy,
as may occur following chemotherapy in testicular teratomas
(Raghavan et al., 1980). It has been suggested that the
epithelial basement membrane provides an effective barrier
to the passage of CA125 from the tumour to the serum
(Fleuren et al., 1987). The high molecular weight of the
antigen (over 500,000 daltons) (Niloff et al., 1985) in the
presence of poor tumour blood flow and intact basement
membranes around tumour acini is the most likely cause of
normal serum CA125 concentrations in the presence of
antigen-rich residual tumour at second laparotomy.
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